Abstract:Adoptive immunotherapy with interleukin 2 (IL-2) and lymphokine-activated killer (LAK) cells (IL-2/LAK) is a technically demanding cancer therapy dependent upon large scale isolation and culture of lymphocytes. An important question is whether this technology can be accomplished routinely outside of highly specialized centers. In addition, no systematic examination of laboratory correlates of IL-2/LAK therapy in humans has been reported to date. The objectives of this report are to address two issues relevant to IL-2/LAK therapy. (a) Can IL-2/LAK therapy be accomplished outside of previously identified centers of expertise? (b) What are the relevant laboratory/clinical parameter correlations? The six institutions in the National Cancer Institute extramural trial treated 83 evaluable patients with renal cancer, malignant melanoma, or colon cancer with IL-2/LAK by a uniform protocol. Patients received 5 days of IL-2 priming, then daily leukaphereses for 5 days starting 48 h after IL-2 to harvest cells. Mononuclear cells were isolated, then cultured in roller bottles in 1-liter aliquots for 3 to 4 days at a cell density of 1.5 x 10(6) per ml with recombinant IL-2, 1500 units per ml. Cells were harvested and administered to patients with additional IL-2. Administration of IL-2 regularly induced lymphopenia and rebound lymphocytosis. Leukapheresis yields and numbers of LAK cells generated in culture and reinfused into patients correlated directly with peak lymphocyte counts achieved by IL-2 administration. Mean mononuclear cell recovery per 5 days of leukapheresis (+/- SEM) was 14.3 +/- 0.8 x 10(10). Average volume of cells cultured per patient was 95 liters (range, 41 to 235). Mean yield of cells harvested from cultures was 53%. Mean total number of LAK cells infused per patient was 7.6 +/- 0.4 x 10(10) (range, 2 to 15.2 x 10(10]. LAK activity was measured in vitro by lysis of 51Cr-labeled natural killer-resistant Daudi and fresh tumor targets. LAK effector cells regularly lysed these targets in vitro. Neither tumor reduction nor clinical toxicity correlated with dose or with cytolytic activity of LAK cells, or with other laboratory parameters including base-line lymphocyte count and IL-2-induced lymphocytosis. We conclude: (a) large quantities of LAK effector cells with tumoricidal activity can be generated routinely at different centers; (b) neither in vitro LAK activity nor numbers of LAK cells infused were predictive of clinical efficacy or toxicity. There is a need to identify other laboratory or clinical parameters more predictive of IL-2/LAK therapeutic efficacy or toxicity.

Evaluation of the treatment of 62 patients with advanced cancer by using lymphokine-activated killer cells plus interleukin-2

Treatment of Patients with Malignant Pleural Effusions Due to Advanced Lung Cancer by Transfer of Autologous LAK Cells Combined with Ril-2 or Ril-2 Alone.

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors

Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Adoptive Immunotherapy with Interleukin-2 & Induced Killer Cells in Non-Small Cell Lung Cancer: A Systematic Review & Meta-Analysis

Treatment of pulmonary metastatic renal-cell carcinoma in 116 patients using inhaled interleukin-2 (IL-2)

Immunotherapy of cancer using interleukin 2: current status and future prospects

Experimental study on antileukemia effects of anti-CD3/interleukin-2 costimulated killer cells and interleukin-2 liposomes plus kappa-selenocarrageenan

IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans

[Clinical Study on Recombinant Human Interleukin-2 (proleukin) in the Treatment of Metastatic Renal Cell Carcinoma].

Preliminary clinical observation of combinational chemo-immunotherapy of R-CHOP and interleukin-2 in patients with diffuse large B-cell lymphoma

Metaphase Ⅲ Study of Recombinant Human Interleukin-2 in the Treatment for Renal Cell Carcinoma with Lung Metastasis

Immunotherapy with IL2 by Constant Infusion and Weekly Doxorubicin

A Pilot Study of Low-Dose Recombinant Interleukin-2 for Acute Lymphoblastic Malignancy after Unmanipulated Allogeneic Blood and Marrow Transplantation

Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique

Analysis of parameters for maximal in vitro proliferation and activation of lymphokine-activated killer cells (LAK)

Treatment of 19 primary hepatocellular carcinoma with homologous LAK/IL-2 infused via hepatic artery in combination with iodized oil and anticancer agent embolization

Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy